Tarceva filed for first-line maintenance use in lung cancer in US and EU
20 March 2009
Malini Guha
Please Login to read the full article.
20 March 2009
Malini Guha
malini.guha@informa.com
OSI Pharmaceuticals/
Genentech and
Roche have submitted applications in the US and EU, respectively, for use of their EGFR-targeted small molecule drug Tarceva (erlotinib) as a first-line maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) who have not progressed following...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
